Modelling the value of innovative treatments for Alzheimer’s disease in the United States

References

• Alzheimer’s Association. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 2020;16(3):391–460.
   Web of Science ®Google Scholar
• Aisen PS, Cummings J, Jack CR, Jr, et al. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther. 2017;9(1):60.
   PubMed Web of Science ®Google Scholar
• Joe E, Ringman JM. Cognitive symptoms of Alzheimer’s disease: clinical management and prevention. BMJ. 2019;367:l6217.
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA. 2019;322(16):1589–1599.
   PubMed Web of Science ®Google Scholar
• Nichols E, Szoeke CE, Vollset SE, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88–106.
   PubMed Web of Science ®Google Scholar
• Heron M. Deaths: leading causes for 2017. Natl Vital Stat Rep. 2019;68(6):1–77.
   PubMedGoogle Scholar
• Cummings J, Lee G, Ritter A, et al. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement. 2020;6(1):e12050.
   Web of Science ®Google Scholar
• Rasmussen J, Langerman H. Alzheimer's disease—why we need early diagnosis. Degener Neurol Neuromuscul Dis. 2019;9:123–130.
   PubMed Web of Science ®Google Scholar
• Dubois B, Padovani A, Scheltens P, et al. Timely diagnosis for Alzheimer’s disease: a literature review on benefits and challenges. J Alzheimers Dis. 2016;49(3):617–631.
   PubMed Web of Science ®Google Scholar
• Leibson CL, Long KH, Ransom JE, et al. Direct medical costs and source of cost differences across the spectrum of cognitive decline: a population-based study. Alzheimers Dement. 2015;11(8):917–932.
   PubMed Web of Science ®Google Scholar
• Kelley AS, McGarry K, Gorges R, et al. The burden of health care costs for patients with dementia in the last 5 years of life. Ann Intern Med. 2015;163(10):729–736.
   PubMed Web of Science ®Google Scholar
• Kelley AS, McGarry K, Bollens‐Lund E, et al. Residential setting and the cumulative financial burden of dementia in the 7 years before death. J Am Geriatr Soc. 2020;68(6):1319–1324.
   PubMed Web of Science ®Google Scholar
• El-Hayek YH, Wiley RE, Khoury CP, et al. Tip of the iceberg: assessing the global socioeconomic costs of Alzheimer’s disease and related dementias and strategic implications for stakeholders. J Alzheimers Dis. 2019;70(2):323–341.
   PubMed Web of Science ®Google Scholar
• Gustavsson A, Pemberton-Ross P, Gomez Montero M, et al. Challenges in demonstrating the value of disease-modifying therapies for Alzheimer’s disease. Expert Rev Pharmacoecon Outcomes Res. 2020;20(6):563–570.
   PubMed Web of Science ®Google Scholar
• Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15(5):455–532.
   Google Scholar
• Jack CR, Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):257–262.
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Goldman DP, Michaud P-C, et al. US pharmaceutical policy in a global marketplace: reducing copays tends to be a robust and welfare-improving policy, while imposing price controls risks high costs in the hope of a relatively modest benefit. Health Affairs. 2008;27(Suppl1):w138–w150.
   Web of Science ®Google Scholar
• Research America. U.S. Investments in medical and health research and development 2013–2018. Arlington (VA): Research America; 2019.
   Google Scholar
• Yin W. Market incentives and pharmaceutical innovation. J Health Econ. 2008;27(4):1060–1077.
   PubMed Web of Science ®Google Scholar
• Blume-Kohout ME, Sood N. Market size and innovation: effects of Medicare Part D on pharmaceutical research and development. J Public Econ. 2013;97:327–336.
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Doshi JA, Garrison LP, Jr, et al. Defining elements of value in health care—a health economics approach: an ISPOR Special Task Force report. Value Health. 2018;21(2):131–139.
   PubMed Web of Science ®Google Scholar
• Schwappach DL. Resource allocation, social values and the QALY: a review of the debate and empirical evidence. Health Expect. 2002;5(3):210–222.
   PubMedGoogle Scholar
• Cook JP, Golec JH, Vernon JA, et al. Real option value and path dependence in oncology innovation. Int J Econ Bus. 2011;18(2):225–238.
   Google Scholar
• Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925–930.
   PubMed Web of Science ®Google Scholar
• Goldman D, Lakdawalla D, Philipson TJ, et al. Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA. Health Econ. 2010;19(10):1109–1116.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
   PubMed Web of Science ®Google Scholar
• National Bureau of Economic Research. Who benefits from new medical technologies? Estimates of consumer and producer surpluses for HIV/AIDS drugs. Cambridge (MA): National Bureau of Economic Research; [cited 2020 Dec 21]. Available from: https://www.nber.org/system/files/working_papers/w11810/w11810.pdf
   Google Scholar
• Neumann PJ, Levine BS. Do HEDIS measures reflect cost-effective practices? Am J Prev Med. 2002;23(4):276–289.
   PubMed Web of Science ®Google Scholar
• Huter K, Kocot E, Kissimova-Skarbek K, et al. Economic evaluation of health promotion for older people-methodological problems and challenges. BMC Health Serv Res. 2016;16(Suppl 5):328.
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Phelps CE. Health technology assessment with risk aversion in health. J Health Econ. 2020;72:102346.
   PubMed Web of Science ®Google Scholar
• Hurd MD, Martorell P, Delavande A, et al. Monetary costs of dementia in the United States. N Engl J Med. 2013;368(14):1326–1334.
   PubMed Web of Science ®Google Scholar
• Lin P-J, D’Cruz B, Leech AA, et al. Family and caregiver spillover effects in cost-utility analyses of Alzheimer’s disease Iinterventions. Pharmacoeconomics. 2019;37(4):597–608.
   PubMed Web of Science ®Google Scholar
• Kosaner Kließ M, Martins R, Connolly MP. Major cost drivers in assessing the economic burden of Alzheimer’s disease: a structured, rapid review. J Prev Alz Dis. 2021:1–9. DOI:https://doi.org/10.14283/jpad.2021.17
   Google Scholar
• Robinson RL, Rentz DM, Andrews JS, et al. Costs of early stage Alzheimer’s disease in the United States: cross-sectional analysis of a prospective cohort study (GERAS-US)1. J Alzheimers Dis. 2020;75(2):437–450.
   PubMed Web of Science ®Google Scholar
• Costa N, Wubker A, De Mauleon A, et al. Costs of care of agitation associated with dementia in 8 European countries: results from the righttimeplacecare study. J Am Med Dir Assoc. 2018;19(1):95 e1–95 e10.
   Web of Science ®Google Scholar
• Pena-Longobardo LM, Rodriguez-Sanchez B, Oliva-Moreno J, et al. How relevant are social costs in economic evaluations? The case of Alzheimer’s disease. Eur J Health Econ. 2019;20(8):1207–1236.
   PubMed Web of Science ®Google Scholar
• Report to the Congress: Medicare and the Health Care Delivery System. Chapter 9: Issues affecting dual-eligible beneficiaries: CMS’s financial alignment demonstration and the Medicare Savings Programs. Washington (DC): Medicare Payment Advisory Committee (US). 2016.
   Google Scholar
• Bunn F, Burn AM, Goodman C, et al. Comorbidity and dementia: a scoping review of the literature. BMC Med. 2014;12:192.
   PubMed Web of Science ®Google Scholar
• Garrison LP, Jr, Neumann PJ, Willke RJ, et al. A health economics approach to US value assessment frameworks–summary and recommendations of the ISPOR Special Task Force Report [7]. Value Health. 2018;21(2):161–165.
   PubMed Web of Science ®Google Scholar